Wells Fargo analyst Yanan Zhu upgraded Spyre Therapeutics to Overweight from Equal Weight with a price target of $35, up from $12. The analyst cites the updated half-life comparison for SPY001 versus vedolizumab in non-human primates, suggesting an over three-times differential, and also proximity to clinical trial initiation and human data for the upgrade. The firm thinks Spyre’s approach of leveraging half-life extension to develop less frequently dosed treatments for the large market of inflammatory bowel disease is promising.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SYRE:
- Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Spyre Therapeutics Revamps Governance and Fiscal Year
- Spyre Therapeutics Announces Board Changes and Compensation Updates
- Spyre Therapeutics Enhances Protection for Executives and Board
- 3 Best Stocks to Buy Now, 1/16/2024, According to Top Analysts
